#LIXTW

StockTitan

@stocktitan.net

1 month ago

DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE LIXTE Biotechnology (Nasdaq: LIXT) is the sponsor of the inaugural Good Health: Mind, Body & Soul Summit led by De La Soul on February 19, 2026 at Morehouse College in Atlanta. The invitation-only event convenes health experts, artists, athletes, researchers, and advocates to advance health equity for Black men and families. Programming covers cancer, heart disease, mental health, addiction, sleep, relationships, and intergenerational wellness, linking science and lived experience. Attendance is by invitation; more information is available at the summit website.

#LIXT #LIXTW DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE

www.stocktitan.net/news/LIXT/de-la-soul-led...

StockTitan

@stocktitan.net

2 months ago

LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial LIXTE (Nasdaq: LIXT) announced an expansion of its ongoing ovarian clear cell cancer trial combining its compound LB-100 with GSK's dostarlimab. The study, initiated in January 2024, will double enrollment from 21 to 42 patients across two sites: MD Anderson and the Robert H. Lurie Comprehensive Cancer Center at Northwestern. The trial is led by Amir Jazaeri, MD, and Emily M. Hinchcliff, MD, MPH. LIXTE expects initial data from the first 21 patients to be presented in the first half of 2026. The company framed the expansion as progress toward evaluating LB-100’s potential to enhance immunotherapy and chemotherapy outcomes.

#LIXT #LIXTW LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial

www.stocktitan.net/news/LIXT/lixte-and-its-...

StockTitan

@stocktitan.net

2 months ago

Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules Lixte Biotechnology (NASDAQ: LIXT) entered definitive agreements for a registered direct offering to raise approximately $4.3 million by selling 1,051,342 Common Units (or Pre-Funded Units) at a public offering price of $4.09 per Common Unit (or $4.08999 per Pre-Funded Unit). Each unit includes one share or one pre-funded warrant plus one common warrant exercisable at $3.96 and expiring 60 months after issuance. Pre-Funded Warrants are immediately exercisable. The offering is priced at the market under Nasdaq rules and is expected to close on or about December 19, 2025. Proceeds are intended for general corporate purposes and working capital.Spartan Capital Securities is exclusive placement agent; offering made from an effective Form S-3 shelf (declared effective May 2, 2024).

#LIXT #LIXTW Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

www.stocktitan.net/news/LIXT/lixte-biotechn...

StockTitan

@stocktitan.net

3 months ago

LIXTE Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment LIXTE Biotechnology (Nasdaq: LIXT) completed the acquisition of UK-based Liora Technologies Europe Ltd. on November 25, 2025, making Liora a wholly owned subsidiary and adding the proprietary LiGHT System (Linac for Image Guided Hadron Therapy) to LIXTE’s assets.The LiGHT System is installed at STFC’s Daresbury Laboratory, where STFC will provide resources to develop a center of excellence. The release notes $300+ million invested to date in developing the technology and describes LIXTE’s plan to pursue a recurring revenue model through jointly operated treatment centers while complementing ongoing LB-100 clinical trials.

#LIXT #LIXTW LIXTE Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment

www.stocktitan.net/news/LIXT/lixte-biotechn...

StockTitan

@stocktitan.net

6 months ago

Cancer Drug Breakthrough: LIXTE's LB-100 Validated in Nature Study as MD Anderson Reports Survival Gains Biotech firm completes $6.5M financing, regains Nasdaq compliance. Nature study validates LB-100 for ovarian/colorectal cancer. New CEO appointed, clinical trials ongoing at MD Anderson, Northwestern.

#LIXT #LIXTW LIXTE Biotechnology Holdings Provides Corporate Update

www.stocktitan.net/news/LIXT/lixte-biotechn...

StockTitan

@stocktitan.net

7 months ago

Clinical-Stage Biotech Makes Bold Move: Plans to Hold Quarter of Treasury in Cryptocurrency Nasdaq-listed pharmaceutical company approves allocation of up to 25% of corporate treasury to Bitcoin and other digital assets. Emphasizes regulated custody approach. Learn more.

#LIXT #LIXTW LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency

www.stocktitan.net/news/LIXT/lixte-biotechn...

StockTitan

@stocktitan.net

8 months ago

New Clinical Findings Published in Scientific Journal Nature Validate LIXTE’s Ongoing Ovarian and Colorectal Cancer Trials LIXTE Biotechnology (NASDAQ:LIXT) announced the publication of significant findings in Nature journal that validate their ongoing clinical trials of LB-100 for ovarian and colorectal cancers. The study, led by researchers at MD Anderson Cancer Center, revealed that patients with PPP2R1A mutations showed improved survival rates with immune checkpoint therapy.The company is currently conducting two clinical trials: one testing LB-100 with dostarlimab for Ovarian Clear Cell Carcinoma (OCCC) at MD Anderson and Northwestern University, and another evaluating LB-100 with atezolizumab for colon cancer at the Netherlands Cancer Institute. Initial results are expected in the second half of 2025.

#LIXT #LIXTW New Clinical Findings Published in Scientific Journal Nature Validate LIXTE’s Ongoing Ovarian and Colorectal Cancer Trials

www.stocktitan.net/news/LIXT/new-clinical-f...

StockTitan

@stocktitan.net

8 months ago

Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market Lixte Biotechnology Holdings (NASDAQ: LIXT), a clinical stage pharmaceutical company, has announced a $5.0 million private placement of securities priced at market. The offering includes 2,382,084 shares of Common Stock (or Pre-funded Warrants), 3,573,130 shares of Series B Convertible Preferred Stock, and 6,355,214 Common Warrants.The transaction structure includes $4.0 million payable at closing and $1.0 million upon effectiveness of the resale registration statement. The Common Warrants have an initial exercise price of $1.00 per share and a 60-month term. Spartan Capital Securities, LLC is serving as the exclusive placement agent.The company plans to use the net proceeds for general corporate purposes and working capital. The closing is expected around July 2, 2025, subject to customary conditions.

#LIXT #LIXTW Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market

www.stocktitan.net/news/LIXT/lixte-biotechn...

StockTitan

@stocktitan.net

11 months ago

Major Breakthrough? LIXTE's Cancer Prevention Drug Could Eliminate Pre-Cancerous Cells in Aging Adults LIXTE partners with Netherlands Cancer Institute to explore LB-100's potential in eliminating pre-cancerous cells. Breakthrough study targets aging population. Full analysis inside.

#LIXT #LIXTW LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100

www.stocktitan.net/news/LIXT/lixte-launches...

StockTitan

@stocktitan.net

11 months ago

LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer LIXTE Biotechnology (LIXT) has announced significant progress in its cancer treatment development programs. The company has initiated two new clinical trials for its lead compound LB-100: a Phase 1b/2 trial combining LB-100 with GSK's dostarlimab-gxly for ovarian clear cell carcinoma, and a trial with the Netherlands Cancer Institute and Roche for unresponsive metastatic colorectal cancer.Key developments include successful patient dosing in both trials, receipt of a USPTO Notice of Allowance for combining LB-100 with cancer immunotherapies, and completion of a $1,050,000 registered direct offering. Two breakthrough studies were published: one in Cancer Discovery showing LB-100's ability to force cancer cells to relinquish malignant properties, and another in EMBO demonstrating how LB-100 makes cancer cells more vulnerable to immunotherapy.

#LIXT #LIXTW LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

www.stocktitan.net/news/LIXT/lixte-biotechn...

StockTitan

@stocktitan.net

1 year ago

New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form LIXTE Biotechnology Holdings (Nasdaq: LIXT) announced new pre-clinical data published in BioXriv and International Journal of Pharmaceutics regarding their lead clinical compound LB-100. The research reveals how LB-100 converts into its active form, endothall, a protein phosphatase inhibitor effective in cancer treatment with immunotherapy.Scientists at the Netherlands Cancer Institute discovered an enzyme that mediates LB-100's conversion into endothall, potentially serving as a biomarker to identify patients most likely to respond to treatment. Additionally, research by BioPharmaWorks showed that while LB-100 can spontaneously convert to endothall through hydrolysis under physiological conditions, this process is slow, with the newly discovered enzymatic conversion accelerating the activation inside cells.The company is currently conducting clinical trials of LB-100 for ovarian cancer and colorectal cancer treatment. These findings will help optimize patient selection for future clinical trials.

#LIXT #LIXTW New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form

www.stocktitan.net/news/LIXT/new-findings-s...

StockTitan

@stocktitan.net

1 year ago

Can LIXTE's Cancer Drug Breakthrough Succeed Where Others Failed? Northwestern Joins Trial LIXTE adds prestigious Northwestern site for LB-100/Dostarlimab combination trial targeting ovarian clear cell carcinoma with high unmet medical needs.

#LIXT #LIXTW LIXTE Adds Northwestern University’s Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer

www.stocktitan.net/news/LIXT/lixte-adds-nor...

StockTitan

@stocktitan.net

1 year ago

LIXTE Biotech (LIXT) Secures Fresh Capital: Strategic $1.05M Direct Offering Includes Warrant Sweetener LIXTE Biotech sells 434,784 shares at $2.415 with 5-year warrants, strengthening its financial position for working capital and corporate initiatives.

#LIXT #LIXTW LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

www.stocktitan.net/news/LIXT/lixte-biotechn...

StockTitan

@stocktitan.net

1 year ago

LIXTE (LIXT) Halts Public Offering Plans: Strategic Shift or Financial Setback? LIXTE Biotechnology cancels Form S-1 Registration Statement for planned public offering, with no securities sold. Company reconsiders funding strategy.

#LIXT #LIXTW LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

www.stocktitan.net/news/LIXT/lixte-biotechn...